Exelixis (EXEL) Cash & Equivalents Growth (1y) (2011 - 2026)

Exelixis (EXEL) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 23.81%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 15.53%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 90.42%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 17.50%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -4.13%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 71.81%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Exelixis 14.44 Bn 13.66 Bn 590.86 Mn 23.07%

Historic Data

Download Data
DateValue
Apr 3, 2026 23.07%
Jan 2, 2026 121.96%
Oct 3, 2025 45.66%
Jul 4, 2025 -17.15%
Apr 4, 2025 -29.21%
Jan 3, 2025 -17.35%
Sep 27, 2024 -34.90%
Jun 28, 2024 -57.27%
Mar 29, 2024 -51.99%
Dec 29, 2023 -47.53%
Sep 29, 2023 -41.23%
Jun 30, 2023 -25.92%
Mar 31, 2023 -25.26%
Dec 30, 2022 -22.56%
Sep 30, 2022 19.03%
Jul 1, 2022 27.32%
Apr 1, 2022 95.37%
Dec 31, 2021 102.74%
Oct 1, 2021 69.83%
Jul 2, 2021 -6.58%